FDA Oversight of Postmarketing Studies

To the Editor: In their Perspective article in this issue of the Journal, Woloshin et al. raise concerns about the status of postmarketing studies after new statutory authority was provided to the Food and Drug Administration (FDA) in the FDA Amendments Act of 2007 (FDAAA). Although the authors…

http://ift.tt/2fdkseQ